Moxetumomab

Moxetumomab is an anti-CD22 human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1][2].

Product Specifications

CAS Number

[1622075-65-3]

UNSPSC

12352203

Target

ADC Antibody; CD22

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/moxetumomab.html

Purity

99.77

Solubility

H2O

Smiles

[Moxetumomab]

Molecular Weight

(146.14 kDa)

References & Citations

[1]Robert J Kreitman, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL) : long-term follow-up from the pivotal trial. J Hematol Oncol. 2021 Feb 24;14 (1) :35.|[2]Sohita Dhillon. Moxetumomab Pasudotox: First Global Approval. Drugs. 2018 Nov;78 (16) :1763-1767.